Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + Everolimus + Dexamethasone in Relapsed ALL
NCT03740334Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2019
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ribociclib and everolimus in acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) (3 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Area Under the Curve from 0 to 24 hours, Maximum Plasma Concentration at 3 years and 3 more. Started Jan 2019; status: active, not recruiting.
02
Drugs
ribociclibeverolimus
03
Conditions
acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03740334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03740334.